The new pharma role you should start training for

European launch team, minus nine months from launch. As we presented our key findings on the patient journey I noticed the brand lead leaning back, like he was trying out if his office chair could work as a temporary bed or something. I recognised the move. An instinctual “this is just too much for me right now” reaction. And I got why he would feel that way. We had just given him evidence that threatened to scrap everything he and his team had done so far in preparing for the launch. What we had presented would need a completely new approach and new capabilities. How on earth would he manage to do all that?

What we had shown him

The launch readiness work had been built around the molecule and the message. The patient journey work was built around something else; where patients actually drop out of the pathway, which referrals fail, which diagnostics arrive too late and which reimbursement gates close before the prescriber even sees a patient.

The findings were not new science. They were the system around the science. And the system was where the launch was going to live or die.

A hypothesis I keep coming back to

The bottleneck for an innovative treatment reaching a European patient is rarely the science. It is rarely the prescribing decision, it is the system around the decision.

If that is the biggest constraint, what current role in pharma would be best equipped to deal with that challenge? It is not the typical rep or KAM and it is not the traditional MSL. It is something else. A scientist with consulting instincts or a consultant with scientific credibility. Someone who can understand a healthcare system the way an MSL understands the science and build a plan to remove patient journey barriers the way a consultant builds a plan to fix a business problem.

The role does not have a real name yet but there’s evidence that our industry is reaching for it.

Notes from the trenches

My research into the topic reveals that initiatives are happening across several European markets.

The hybrid MSL is the most visible sign. Certification programmes in Germany, France and the Netherlands are blending MSL training with real-world evidence work, clinical monitoring, and access coordination. Bayer, Sanofi and IQVIA are hiring into the role. Reported salary uplifts of twenty-five to forty-four percent for people who cross-train.

The cardio-renal launch model has what it takes to become a new standard: One MSL connects the cardiologist, the nephrologist, the primary care lead and the reimbursement team around a single patient pathway.

This is the industry’s instinct telling it that what healthcare decision makers needs and wants is help and support with patient pathway construction.

And I believe that instinct is right.

What it takes to make it work

If this is the role of the next decade, four things have to be true.

The patient journey intelligence has to exist. You cannot consult on a patient journey you have not mapped. The barriers, the pivot points, the gaps between guideline and practice are not assumptions to make in a workshop. They are evidence questions. The role starts with a journey database, not a brand plan.

The capability has to be built. Listening, hypothesising, co-designing. These are consulting skills. They sit closer to a management consulting graduate programme than to the communication models pharma currently runs. Pharma does not yet develop them at scale.

The compensation has to follow the work. As long as the bonus is structured against prescription volume or activity counts, the role drifts back into selling. The KPIs have to attach to barriers removed, pathways built, access secured.

The org chart has to bend. The role does not sit cleanly in medical or in commercial. It coordinates across both, plus access, plus regulatory, sometimes external partners. The team is built around the patient journey, not the function.

A note to you, reading this

If you are in a customer-facing role in European pharma today, the current restructuring will impact your own career. Field force headcount in large pharma has continued to contract through 2025. The hybrid roles described above are growing, with salary uplifts of a third or more for people who cross the boundary. Both numbers point the same way.

You can wait for your employer’s development plan to catch up.

Or you can decide that the role in this article is the role you intend to be doing in five years, and start building the capabilities now.

Patient journey reading. Hypothesis under uncertainty. Consulting craft. Cross-functional fluency. The willingness to walk into a stakeholder conversation without a script.

None of these are mysteries. They are skills, and skills are learnable. Pick one. Start this quarter. The first hour is yours to schedule.

The permission

Pharma is reaching for the right role, early signs are visible across European markets.

The leader who builds it first does not have to invent the science behind it. The patient journey work already tells us what to fix. The capability work already exists for people willing to learn it.

What is needed is not another debate. It is the first step.

Yours, this quarter.